

Clean Version of Claim Amendments

Sub 23
1. (Twice Amended) A method for treating or preventing gastritis in a subject, comprising peripherally administering to said subject a therapeutically effective amount of an amylin or an amylin agonist, wherein said amylin agonist is not a calcitonin or a CGRP.

C1
2. (Twice Amended) A method for treating or preventing gastric ulceration in a subject, comprising peripherally administering to said subject a therapeutically effective amount of an amylin or an amylin agonist, wherein said amylin is not a calcitonin or a CGRP.

Sub 26
14. (New) The method of claim 1 or 2 wherein said IC₅₀ of said amylin or amylin agonist is about 50 pM or less.

19
15. (New) The method of claim 1 or 2 wherein said gastritis or gastric ulceration is induced by a member selected from the group consisting of ethanol and NSAIDs.

20
16. (New) The method of claim 15 wherein said member is ethanol.

20
17. (New) A method for treating or preventing an ethanol-induced gastritis or gastric ulceration in a subject, comprising administering to said subject a therapeutically effective amount of an amylin or an amylin agonist.

C2
18. (New) The method of claim 17 wherein said amylin or amylin agonist has an IC₅₀ of about 50 pM or less.

Sub 27
19. (New) The method of claim 14 wherein said amylin or amylin agonist has an IC₅₀ of about 30 pM or less.

22
20. (New) The method according to claim 12 wherein said route is nasal.

23
21. (New) The method according to claim 12 wherein said route is oral.

24
22. (New) The method according to claim 12 wherein said route is pulmonary.

25
23. (New) The method according to claim 12 wherein said route is transdermal.

26
24. (New) The method according to claim 12 wherein said route is buccal.